VALENCIA, SPAIN--(Marketwired - Mar 10, 2017) - Zenosense,
Inc. (OTCQB: ZENO)
("Zenosense," the "Company"), a healthcare technology company
primarily focused on the development and commercialization of MIDS
Cardiac™, a Point of Care ("POC") handheld device for the early
detection of certain cardiac event biomarkers to significantly
accelerate the triage, diagnosis, treatment and disposition of
patients reporting chest pain and with suspected acute myocardial
infarction (heart attack), is pleased to announce that MIDS Medical
Limited ("MML"), our joint venture based at Sci-Tech, Daresbury
(UK), has completed a first phase of quantitative testing on its
primary bench reader and has conducted preliminary testing on
a secondary bench reader designed to examine two methods of
magnetic nanoparticle detection.
Priority testing was conducted on a second iteration of the
primary test rig designed to simulate MML's "Lab-on-Chip" detection
method. Progressively smaller sample volumes, from 400 nl down to
25 nl of 15.2 nm magnetite nanoparticles in 5 mg/ml aqueous
solution, were dosed into sample wells located in a "test slide"
and detected on the test rig. Key outputs from this testing
indicate:
- Excellent linearity of average system output signal against
sample drop volume.
High levels of output signal, even at the smallest sample
volumes.
MML is delighted with these results which meet a key development
milestone in proving the principle of quantitative
detection.
The next stage of the preplanned development program, now being
specified, is to develop a "Hybrid Strip" to be used in conjunction
with a newly designed test rig, to simulate a final Lab-on-Chip
design. This simulation will not require the bespoke sensor
anticipated to be embodied in a final commercial design. MML
believes the Hybrid Strip will offer a number of important testing
enhancements:
- Positioning; the Hybrid Lab-on Chip strip is expected to
improve the accurate positioning of the nano-particles in the
system relative to our bespoke magnetic sensor, which will enable
more consistent detection.
Proximity; the current standoff from the highly focused
magnetic sensor to the detected particles of around 450 nm
will be reduced to just the sensor packaging in the Lab-on-Chip
configuration which is expected to result in greatly improved
detection of low numbers of nano-particles.
Electronics; there are a number of areas where the supporting
electronics can be optimized, including improved shielding.
Together, these developments are expected to materially enhance
the already extremely promising detection results. Once completed,
the data and results from the Hybrid Strip should allow a final
Lab-on-Chip design, with the standoff fully minimized to maximize
sensitivity of detection. MML, given the results so far, believes
that the MIDS Lab-on-Chip system will be capable of servicing a
high sensitivity troponin test.
Preliminary testing was also conducted on a first iteration of
the secondary rig designed to explore the viability of detection by
a "Magnetic Bridge" structure, for which MML submitted a patent
application on January 19, 2017. This testing proved detection in
principle. Based on these results MML intends to design and
construct a second, magnetically more powerful iteration of this
rig with an improved design to enhance the detection ability and
sensitivity of the system. MML is hopeful that this will yield
similar results to the Lab-on-Chip simulation results described
above.
We believe that, in addition to cardiac markers, the MIDS
technology platform can be applied across a wide spectrum of
diagnostic tests. Proof of detection is the first step in applying
the MIDS technology to cardiac markers and other immunoassay tests.
The Company believes there is an enormous potential market for
highly accurate cardiac marker assays conducted by a hand held
device at the POC. The Company's target is to develop a hand-held
device which can achieve Gold Standard laboratory accuracy or
better, with results delivered at the POC within minutes.
About Zenosense, Inc.
Zenosense, Inc.'s primary focus, through our joint venture
ownership in MIDS Medical Ltd., is the development of a
cost-effective, hand-held Point of Care rapid cardiac diagnostic
device, MIDS Cardiac™, and is also the holder of an exclusive
global license agreement to develop and market effective medical
devices for use in hospitals and primary healthcare settings
targeting the early detection of both deadly bacteria and certain
cancers in the exhaled breath of patients.
To find out more about Zenosense (OTCQB: ZENO),
visit our website at www.zenosense.com.
Forward-Looking Statements
Statements in this news release that are not statements of
historical fact are forward-looking statements, which are subject
to certain risks and uncertainties. Forward-looking statements
can often be identified by words such as "expects," "intends,"
"plans," "may," "could," "should," "anticipates," "likely,"
"believes" and words of similar import. Forward-looking
statements are based on current facts and analyses and other
information that are based on forecasts of future results,
estimates of amounts not yet determined and assumptions of
management. Actual results may differ materially from those
expressed or implied by forward-looking statements due to a variety
of factors that may or may not be foreseeable or within the
reasonable control of the Company. Readers are cautioned not
to place undue reliance on such forward-looking
statements. Additional information on risks and other factors
that may affect the business and financial results of the Company
can be found in filings of the Company with the U.S. Securities and
Exchange Commission, including without limitation the section
entitled "Risk Factors" in the Company's Annual Report on Form 10-K
for the year ended December 31, 2015 filed on filed on May 23,
2016, and in Company reports filed subsequently
thereto. Except as otherwise required by law, the Company
disclaims any obligations or undertaking to publicly release any
updates or revisions to any forward-looking statement contained in
this news release to reflect any change in the Company's
expectations with regard thereto or any change in events,
conditions or circumstances on which any such statement is based.
Respective statements concerning the development of both MIDS
Cardiac™ and other devices under development have been made based
on information obtained from MIDS Medical Ltd. and Zenon Biosystem,
which the Company believes to be accurate, but have not been
independently verified.